DK0470117T3 - Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner - Google Patents

Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner

Info

Publication number
DK0470117T3
DK0470117T3 DK90906216.8T DK90906216T DK0470117T3 DK 0470117 T3 DK0470117 T3 DK 0470117T3 DK 90906216 T DK90906216 T DK 90906216T DK 0470117 T3 DK0470117 T3 DK 0470117T3
Authority
DK
Denmark
Prior art keywords
pct
calcitonin gene
drugs
manufacture
treatment
Prior art date
Application number
DK90906216.8T
Other languages
Danish (da)
English (en)
Inventor
Georg Stief
Original Assignee
Georg Stief
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georg Stief filed Critical Georg Stief
Application granted granted Critical
Publication of DK0470117T3 publication Critical patent/DK0470117T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK90906216.8T 1989-04-27 1990-04-21 Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner DK0470117T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3913954A DE3913954A1 (de) 1989-04-27 1989-04-27 Arzneimittel zur behandlung erektiler dysfunktionen
DE3943519A DE3943519A1 (de) 1989-04-27 1989-04-27 Arzneimittel zur behandlung erektiler dysfunktionen

Publications (1)

Publication Number Publication Date
DK0470117T3 true DK0470117T3 (da) 1994-03-14

Family

ID=25880357

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90906216.8T DK0470117T3 (da) 1989-04-27 1990-04-21 Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner

Country Status (11)

Country Link
US (1) US5214030A (ja)
EP (1) EP0470117B1 (ja)
JP (1) JPH0662429B2 (ja)
AT (1) ATE100714T1 (ja)
AU (1) AU635533B2 (ja)
CA (1) CA2050303C (ja)
DE (3) DE3943519A1 (ja)
DK (1) DK0470117T3 (ja)
HU (1) HU206833B (ja)
RU (1) RU2016578C1 (ja)
WO (1) WO1990012586A1 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
EP0527774A4 (en) * 1990-04-10 1993-03-31 The University Of Melbourne Calcitonin gene related peptide for the treatment of undescended testicles
DE69130529T2 (de) * 1990-04-25 1999-06-02 Vivus Inc Behandlung von erektionversagen
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
BR9203277A (pt) * 1992-08-21 1994-03-01 Cesar Roberto Dias Nahoum Utilizaccao de drogas eretogenicas e respectivas metodologias de aplicacao
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
JP3204510B2 (ja) * 1993-04-05 2001-09-04 コンペティティブ テクノロジーズ，インク． 勃起不全の診断および治療
US5567679A (en) * 1993-12-13 1996-10-22 Daly; Theodore J. Use of CGRP in treating alopecia
JPH0827018A (ja) * 1994-07-22 1996-01-30 Sanwa Kagaku Kenkyusho Co Ltd 生理活性ペプチド又は蛋白質を含有する薬剤組成物
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5958877A (en) * 1995-05-18 1999-09-28 Wimalawansa; Sunil J. Method for counteracting vasospasms, ischemia, renal failure, and treating male impotence using calcitonin gene related peptide
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
DE19548345C2 (de) * 1995-12-22 1998-10-15 Henkel Kgaa Verwendung von Mischungen spezieller Emulgatoren und Ölkörpern
US6271211B1 (en) 1997-02-13 2001-08-07 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating penile smooth muscle tone
US6239117B1 (en) 1997-02-13 2001-05-29 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for regulating bladder smooth muscle tone
US6150338A (en) * 1997-02-13 2000-11-21 Albert Einstein College Of Medicine Of Yeshiva University Gene therapy for alleviating erectile dysfunction
US7030096B1 (en) * 1997-02-13 2006-04-18 Albert Einstein College Of Medicine Of Yeshiva University Method of enhancing relaxation of penile smooth muscle by introduction of DNA encoding maxi-K potassium channel protein
US6211156B1 (en) * 1999-11-10 2001-04-03 Asta Medica A.G. Peptides for treatment of erectile dysfunction
US6809079B2 (en) * 2002-01-08 2004-10-26 Vasogenix Pharmaceuticals, Inc. Compositions and methods for treating female sexual arousal disorder using hydrophobic-calcitonin gene related peptide
DE202004006803U1 (de) * 2004-04-28 2004-07-08 Brücker, Achim, Dr.med. Kondom mit einer Beschichtung und Zusammensetzung
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
KR101130283B1 (ko) 2009-07-22 2012-03-26 부경대학교 산학협력단 평활근 이완활성을 지닌 칼시토닌 관련 펩타이드

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5374618A (en) * 1983-06-15 1994-12-20 Celltech Limited Calcitonin peptides, and gene related pharmaceutical compositions
US4530838A (en) * 1983-07-08 1985-07-23 The Salk Institute For Biological Studies Synthetic calcitonin-gene-related peptides for lowering blood pressure or gastric acid secretion in mammals
GB8327346D0 (en) * 1983-10-12 1983-11-16 Morris H R Peptide
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4687839A (en) * 1985-12-23 1987-08-18 Kempe Tomas G Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents

Also Published As

Publication number Publication date
HU206833B (en) 1993-01-28
DE3913954C2 (ja) 1991-08-29
RU2016578C1 (ru) 1994-07-30
CA2050303C (en) 1995-05-30
DE3943519A1 (de) 1991-01-17
DE3913954A1 (de) 1990-10-31
HU903425D0 (en) 1991-12-30
HUT59833A (en) 1992-07-28
WO1990012586A1 (de) 1990-11-01
JPH0662429B2 (ja) 1994-08-17
JPH04504856A (ja) 1992-08-27
US5214030A (en) 1993-05-25
EP0470117A1 (de) 1992-02-12
ATE100714T1 (de) 1994-02-15
AU5446590A (en) 1990-11-16
AU635533B2 (en) 1993-03-25
EP0470117B1 (de) 1994-01-26
DE59004445D1 (de) 1994-03-10

Similar Documents

Publication Publication Date Title
DK0470117T3 (da) Anvendelse af "calcitonin gene-related peptides" til fremstilling af lægemidler til behandling af erektile dysfunktioner
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DK2016950T3 (da) Farmaceutisk sammensætning omfattende et exendin-4-peptid
HK1003978A1 (en) Composition for the treatment of schizophrenia
DE69006628D1 (de) Pharmazeutische Zusammensetzung, enthaltend Loratadin, Ibuprofen und Pseudoephedrin.
BR9607926A (pt) Composição farmacêutica para o tratamento de hiperfosfatemia uso de carbonato de lantânio processo para a preparação de carbonato de lantânio e carbonato de lantânio
PT699686E (pt) Fragmentos de peptido insulinotropico do tipo glucagona biologicamente activos
DE69115247T2 (de) Behandlung von fettleibigkeit mit einem alpha-2-adrenergen-agonisten und einem wachstumshormon freigebenden peptid.
DE3889536D1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
TR199501630A2 (tr) Peptid p277 benzerleri ve diagnoz ve dibetlerin'lerin tedavisi icin onlari iceren kompozisyonlar.
SE9702401D0 (sv) Pharmaceutical use
EP0981360A4 (en) METHOD FOR PREVENTING GASTRITIS USED BY AMYLIN OR AMYLIN AGONISTS
DE69420145D1 (de) Behandlung präkanzeröser läsionen durch muramylpeptide
ES2109234T3 (es) Metodo de tratamiento de la uveorretinitis autoinmune en el hombre.
ATE221123T1 (de) Glykoprotein-hormonrezeptor-moleküle
ATE3416T1 (de) Pharmakologisch aktive peptide und diese enthaltende arzneimittel.
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto
ES2101311T3 (es) Utilizacion de un dispositivo transdermico que contiene (e)-2-(p-fluorofenetil)-3-fluoroalilamina y su uso para el tratamiento de la enfermedad de alzheimer.
SE8800461D0 (sv) Farmaceutisk komposition
DE3162674D1 (en) A purified polypeptide, a process for its preparation, its use and pharmaceutical compositions containing it